Minuto F, Del Monte P, Barreca A, Fortini P, Cariola G, Catrambone G, Giordano G
Cancer Res. 1986 Feb;46(2):985-8.
Immunoreactive somatomedin-C/insulin-like growth factor I (SM-C/IGF I) content was measured in human neoplastic lung tissue obtained from surgery on 10 patients (seven epidermoid carcinoma, three adenocarcinoma), and in normal lung tissue obtained from the same excised portion. SM-C/IGF I content in lung tumors was 615 +/- 123 (SE) milliunits/g of tissue (range, 214-1531), significantly higher (P less than 0.01) than normal tissue (234 +/- 51 milliunits/g of tissue; range, 37-537); in particular, every subject showed a clear-cut difference of SM-C/IGF I content between neoplastic and normal tissue (ratio, 3.41 +/- 0.69; range, 1.4-7.2). The results were essentially unchanged when data were expressed relative to hemoglobin or DNA tissue content. By contrast, in peripheral plasma SM-C/IGF I concentration was 0.51 +/- 0.17 units/ml, significantly lower (P less than 0.01) than in 59- to 70-yr-old control subjects (1.10 +/- 0.13 units/ml). In conclusion, the lung tumors studied, irrespective of their histological structure, contain more SM-C/IGF I than does normal tissue. Whether this is due to a primary in situ production of SM-C/IGF I or is secondary to overproduction of other inducers such as platelet derived growth factor-like peptides is yet to be clarified. The reduced circulating SM-C/IGF I concentration seems to be related more to the nutritional status of the patients.
对10例接受手术的患者（7例为鳞状细胞癌，3例为腺癌）的人肿瘤肺组织以及取自同一切除部位的正常肺组织中的免疫反应性生长调节素C/胰岛素样生长因子I（SM-C/IGF I）含量进行了测定。肺肿瘤组织中SM-C/IGF I含量为615±123（SE）毫单位/克组织（范围为214 - 1531），显著高于正常组织（234±51毫单位/克组织；范围为37 - 537）（P<0.01）；特别是，每个受试者的肿瘤组织与正常组织之间的SM-C/IGF I含量均有明显差异（比值为3.41±0.69；范围为1.4 - 7.2）。当数据以相对于血红蛋白或DNA组织含量表示时，结果基本不变。相比之下，外周血中SM-C/IGF I浓度为0.51±0.17单位/毫升，显著低于59至70岁对照组受试者（1.10±0.13单位/毫升）（P<0.01）。总之，所研究的肺肿瘤，无论其组织结构如何，所含SM-C/IGF I均多于正常组织。这是由于SM-C/IGF I的原位原发性产生，还是继发于其他诱导剂（如血小板衍生生长因子样肽）的过度产生，尚待阐明。循环中SM-C/IGF I浓度降低似乎与患者的营养状况关系更大。
